Acute radiation syndrome (ARS) occurs when hematopoietic or gastrointestinal cells are damaged by radiation exposure causing DNA damage to the bone marrow and gastrointestinal epithelial stem cell populations. In these highly proliferative cell types, DNA damage inhibits stem cell repopulation. In humans and animals, this inability to regenerate stem cells is lethal. Within this manuscript, several compounds, Amifostine, Captopril, Ciprofloxacin, PrC-210, 5-AED (5-androstene-3β,17β-diol), and 5-AET (5-androstene-3β,7β,17B-triol), are assessed for their ability to protect against ARS in an in vitro and/or in vivo setting. ARS was accomplished by irradiating mouse bone marrow cells or rat intestinal epithelial (IEC-6) cells in vitro with 4–8 Gy and in vivo by exposing Mus musculus to 7.3 Gy of whole-body irradiation. The primary endpoints of this study include cellular viability, DNA damage via γ-H2AX, colony formation, and overall survival at 30-days post-irradiation. In addition to evaluating the radioprotective performance of each compound, this study establishes a distinct set of in vitro assays to predict the overall efficacy of potential radioprotectors in an in vivo model of ARS. Furthermore, these results highlight the need for FDA-approved medical intervention to protect against ARS.

Despite significant advancement in cancer treatments, therapies with minimal toxicity to healthy cells are still limited. One targetable weakness of cancer cells is their sensitivity to oxidative stress. We find that the combination of two antioxidants—the common food additive tert-butylhydroquinone (tBHQ) and a manganese porphyrin in clinical trials, MnTnBuOE-2-PyP5+—increases oxidative stress and causes apoptotic death in several cancer cell lines, but not in mouse primary fibroblasts. Investigating the mechanism of cell death, MnTnBuOE-2-PyP5+ catalyzes the oxidation of tBHQ, producing the electrophilic quinone tert-butylquinone (tBQ). A critical role for tBQ and its electrophilic character was revealed with the observation that di-tert-butylhydroquinone (dtBHQ) in combination with MnTnBuOE-2-PyP5+ causes no observable oxidative stress and is non-toxic, despite rapid oxidation to di-tert-butylquinone (dtBQ), a non-electrophilic quinone. Cell death from the combination of tBHQ and MnTnBuOE-2-PyP5+ is completely dependent on the generation of hydrogen peroxide, as shown by the inclusion of catalase. This system, in which two non-toxic molecules in combination cause specific toxicity to cancer cells, is a potential means to kill cancer cells in a targeted manner.

Despite significant advancement in cancer treatments, therapies with minimal toxicity to healthy cells are still limited. One targetable weakness of cancer cells is their sensitivity to oxidative stress. We find that the combination of two antioxidants—the common food additive tert-butylhydroquinone (tBHQ) and a manganese porphyrin in clinical trials, MnTnBuOE-2-PyP⁵⁺ (MnBuOE)—increases oxidative stress and causes apoptotic death in several cancer cell lines, but not in mouse primary fibroblasts. Investigating the mechanism of cell death, MnBuOE is observed to catalyze the oxidation of tBHQ, producing the electrophilic quinone tert-butylquinone (tBQ). A critical role for tBQ and its electrophilic character was revealed with the observation that di-tert-butylhydroquinone (dtBHQ) in combination with MnBuOE causes no observable oxidative stress and is non-toxic, despite rapid oxidation to di-tert-butylquinone (dtBQ), a non-electrophilic quinone. Cell death from the combination of tBHQ and MnBuOE appears to be completely dependent on the generation of hydrogen peroxide, as shown by the inclusion of catalase. This system, in which two non-toxic molecules in combination cause specific toxicity to cancer cells, is a potential means to kill cancer cells in a targeted manner.